Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15470279 | 0.87 | TLR7 (0.46) | TLR7TLR8KCNH2 | |
| SCHEMBL23472393 | 0.86 | TLR7 (0.40) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL20219553 | 0.78 | TLR7 (0.44) | TLR7TLR8KCNH2 | |
| SCHEMBL15469944 | 0.75 | TLR7 (0.43) | TLR7TLR8KCNH2 | |
| SCHEMBL19274182 | 0.75 | TLR7 (0.43) | TLR7TLR8KCNH2 | |
| SCHEMBL23185623 | 0.75 | TLR7 (0.43) | TLR7TLR8 | |
| SCHEMBL21693478 | 0.73 | TLR7 (0.50) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL21919317 | 0.72 | TLR7 (0.39) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL22825028 | 0.72 | TLR7 (0.43) | P2RX3P2RX2TLR7TLR8KCNH2 | |
| SCHEMBL20025838 | 0.72 | TLR7 (0.43) | P2RX3P2RX2TLR7TLR8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903967-B3 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-04-15 | — | — | EP | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, ENTPD5 | P2RX3 938/4885P2RX2 779/4885TLR7 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.